Skip to content
Clinical Trials – home

Unidade Local De Saude Da Guarda E.P.E.

Research site

Portugal Avenida Rainha Dona Amelia 19, 6300-749 Guarda, Portugal

  • 5 trials recruiting
  • Chronic obstructive pulmonary disease · Dry eye · Sjogren's syndrome
  • Adults and children

About Specializations

Unidade Local De Saude Da Guarda E.P.E. in Guarda, Portugal specialises in clinical trials of conditions such as Chronic obstructive pulmonary disease, Dry eye, Sjogren's syndrome, Systemic lupus erythematosus, and other specialisations. This site conducts important research.

Main research areas of the site

Immune System and Rheumatology Research

At Unidade Local De Saude Da Guarda E.P.E., clinical trials in immune system diseases and musculoskeletal diseases focus on conditions such as systemic lupus erythematosus, rheumatoid arthritis, psoriatic arthritis, and Giant Cell Arteritis. These studies are designed to test new therapies and assess whether they can better control inflammation, improve symptoms, and support long-term disease management.

  • Evaluating new treatment options for systemic lupus erythematosus and related autoimmune conditions
  • Studying therapies for rheumatoid arthritis and psoriatic arthritis to reduce joint and axial disease activity
  • Assessing treatment effectiveness and safety in Giant Cell Arteritis
  • Exploring improved control of chronic inflammatory disease in rheumatology care

These trials reflect a strong focus on advanced rheumatology research, with the goal of offering better options for patients living with persistent autoimmune and inflammatory disorders.

Respiratory Disease Studies

Research in respiratory tract diseases at this site includes studies in chronic obstructive pulmonary disease and severe asthma with an eosinophilic phenotype. The main purpose is to evaluate new approaches that may reduce flare-ups, improve breathing, and help patients maintain better daily lung function.

  • Testing therapies for chronic obstructive pulmonary disease to lower exacerbation rates
  • Investigating treatment options for severe asthma with eosinophilic inflammation
  • Measuring whether new respiratory therapies can improve symptom control and long-term outcomes
  • Supporting better management of chronic airway inflammation

This area highlights ongoing efforts in pulmonology to improve both symptom relief and disease control for people with difficult-to-treat respiratory conditions.

Cardiovascular and Metabolic Inflammation Trials

Clinical research in cardiovascular diseases and related inflammatory conditions includes studies in heart failure with preserved or mildly reduced ejection fraction. These trials aim to determine whether new treatments can lower the risk of serious heart events and improve outcomes in patients with systemic inflammation.

  • Evaluating therapies for heart failure linked with inflammation
  • Assessing whether treatment can reduce cardiovascular complications and improve overall stability
  • Studying new options for patients with persistent inflammatory burden and heart disease
  • Exploring better ways to support long-term cardiovascular health

The work at Unidade Local De Saude Da Guarda E.P.E. shows a growing interest in the connection between cardiology and inflammation, with research aimed at improving treatment effectiveness in complex heart disease.

Digestive, Infectious, and Liver Disease Research

Trials in digestive system diseases and bacterial infections examine conditions such as non-alcoholic steatohepatitis and Clostridioides difficile infection, as well as prevention of post-surgical infection. The purpose of this research is to improve disease control, reduce recurrence, and strengthen infection prevention after surgery.

  • Studying therapies for non-alcoholic steatohepatitis and liver inflammation
  • Testing strategies to prevent recurrent Clostridioides difficile infection
  • Evaluating infection prevention after abdominal surgery
  • Improving outcomes in gastroenterology and infection control

These studies combine hepatology, infectious disease, and surgical prevention research to address important causes of morbidity in everyday clinical care.

Oncology and Targeted Treatment Research

Within neoplasms, the site is involved in studies for unresectable or metastatic HER2+ colorectal cancer. The focus is on evaluating whether new treatment combinations can improve disease control and delay progression in advanced cancer.

  • Assessing treatment effectiveness in advanced colorectal cancer
  • Studying targeted approaches for HER2-positive disease
  • Measuring whether new therapies can extend progression-free survival
  • Supporting research in advanced oncology care

This line of research reflects an effort to refine cancer therapy for patients with limited treatment options and more advanced disease.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Avenida Rainha Dona Amelia 196300-749 GuardaPortugal
Recruiting now
5 trials
Conditions studied
15

More sites in GuardaPortugal

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

17 clinical trials

Study of Tucatinib, Trastuzumab, and mFOLFOX6 for Patients with HER2+ Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Seagen Inc.

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

A Study of Depemokimab Compared to Placebo in Adults with Chronic Obstructive Pulmonary Disease and Type 2 Inflammation

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Cenerimod
  • Sponsor:Viatris Innovation GmbH

Study on VE303 for Preventing Recurrent C. difficile Infection in Patients

Investigational
Countries:PortugalPortugal
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bacilli, Cluster Xvii, Strain Relative Clostridium_Aq Innocuum, Live
  • Sponsor:Vedanta Biosciences Inc.

Type 2 diabetes mellitus

Not yet recruiting

Efficacy and Safety of Alogliptin Plus Empagliflozin Compared with Alogliptin Alone or Empagliflozin Alone in Adults with Type 2 Diabetes on Metformin

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Alogliptin
  • Sponsor:Tecnimede-Sociedade Tecnico-Medicinal S.A.

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Psoriatic arthropathy

Not recruiting

Study on Guselkumab for Treating Psoriatic Arthritis in Patients New to Biologic Therapy

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Study on the Effects of Semaglutide in Patients with Non-Alcoholic Steatohepatitis (NASH) and Fibrosis Stages 2 or 3

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Giant cell arteritis

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib and Prednisolone in Patients with Giant Cell Arteritis

Registered drug
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Prednisolone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Itepekimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Study on Preventing Infections After Abdominal Surgery Using D-PLEX with Doxycycline Hyclate for Patients Undergoing Abdominal Surgery

InvestigationalNo placebo
Countries:PortugalPortugal
  • Participants:18–64 years · 65+ years
  • Substances:Doxycycline Hyclate
  • Sponsor:Polypid Ltd.
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.